X4 PHARMACEUTICALS, INC Payments for Repurchase of Convertible Preferred Stock
X4 PHARMACEUTICALS, INC (XFOR) reported Payments for Repurchase of Convertible Preferred Stock of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock · last filed 2021-03-19
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for the quarter ending 2019-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for the quarter ending 2018-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for the quarter ending 2018-09-30 was -$34.00K.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for the quarter ending 2018-06-30 was $34.00K.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for fiscal 2020 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for fiscal 2018 was $1.13M.
- X4 PHARMACEUTICALS, INC payments for repurchase of convertible preferred stock for fiscal 2017 was $0.00.
| Period end | Payments for Repurchase of Convertible Preferred Stock 3 month | Payments for Repurchase of Convertible Preferred Stock 6 month | Payments for Repurchase of Convertible Preferred Stock 9 month | Payments for Repurchase of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-19 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $0.00 10-K · filed 2021-03-19 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$34.00K derived: sum of 2 quarters · filed 2021-03-19 | $0.00 derived: sum of 3 quarters · filed 2021-03-19 | $1.13M 10-K · filed 2021-03-19 |
| 2018-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $1.13M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.16M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $1.13M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |